Jefferies Financial Group Cuts Elevance Health (NYSE:ELV) Price Target to $395.00

Elevance Health (NYSE:ELV) had its price objective trimmed by Jefferies Financial Group from $401.00 to $395.00 in a report issued on Friday,MarketScreener reports. The firm currently has a buy rating on the stock.

A number of other equities analysts also recently weighed in on the company. The Goldman Sachs Group began coverage on Elevance Health in a report on Tuesday, October 14th. They issued a “neutral” rating and a $343.00 target price on the stock. Truist Financial set a $400.00 price objective on shares of Elevance Health in a research report on Tuesday, October 14th. TD Cowen reiterated a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Leerink Partners boosted their price target on shares of Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a report on Thursday. Finally, Barclays dropped their price target on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a research note on Friday. Thirteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $396.90.

Elevance Health Trading Down 0.4%

NYSE ELV opened at $345.62 on Friday. The firm’s 50 day moving average price is $351.69 and its two-hundred day moving average price is $328.87. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.56 and a current ratio of 1.54. Elevance Health has a twelve month low of $273.71 and a twelve month high of $458.75. The stock has a market cap of $76.81 billion, a price-to-earnings ratio of 13.76, a PEG ratio of 1.93 and a beta of 0.50.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The business had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities analysts anticipate that Elevance Health will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a yield of 2.0%. Elevance Health’s dividend payout ratio (DPR) is currently 27.23%.

Institutional Trading of Elevance Health

Several large investors have recently made changes to their positions in ELV. Delta Investment Management LLC lifted its position in Elevance Health by 21.5% during the 4th quarter. Delta Investment Management LLC now owns 28,692 shares of the company’s stock worth $10,058,000 after acquiring an additional 5,080 shares during the last quarter. Simplicity Wealth LLC increased its stake in shares of Elevance Health by 20.0% in the fourth quarter. Simplicity Wealth LLC now owns 1,220 shares of the company’s stock worth $428,000 after purchasing an additional 203 shares during the period. Joel Isaacson & Co. LLC lifted its position in shares of Elevance Health by 45.1% during the 4th quarter. Joel Isaacson & Co. LLC now owns 2,561 shares of the company’s stock worth $898,000 after purchasing an additional 796 shares during the last quarter. Pekin Hardy Strauss Inc. boosted its stake in Elevance Health by 448.0% during the 4th quarter. Pekin Hardy Strauss Inc. now owns 9,618 shares of the company’s stock valued at $3,372,000 after purchasing an additional 7,863 shares during the period. Finally, Keybank National Association OH boosted its stake in Elevance Health by 1.5% during the 4th quarter. Keybank National Association OH now owns 9,104 shares of the company’s stock valued at $3,191,000 after purchasing an additional 132 shares during the period. Institutional investors own 89.24% of the company’s stock.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 earnings beat consensus (EPS beat and strong profit print), which sparked an earlier rally and helped lift investor sentiment. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Leerink Partners nudged its price target up to $357 and maintained a “market perform” rating, a modest vote of confidence that signals upside potential from current levels. Leerink Partners adjusts price target on Elevance Health to $357
• Positive Sentiment: Consensus broker sentiment remains constructive (average “Moderate Buy”), which provides some support for the shares as analysts digest results and guidance. Elevance Health, Inc. Given Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Company Q4 call and published highlights provide detail on membership shifts, margin dynamics and the drivers behind the quarter — useful for longer-term modeling but not a clear immediate catalyst. ELV Q4 2025 Earnings Call Highlights
• Negative Sentiment: Management forecast for 2026 profit came in below some Street estimates and flagged an anticipated revenue decline, which is the principal near-term headwind pressuring the stock. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Analysts and commentary highlighted margin pressures and membership shifts shaping a weaker 2026 outlook — narratives that have driven selloffs despite the quarterly beat. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts
• Negative Sentiment: Regulatory context: a CMS proposal for only a modest Medicare Advantage rate increase added to near-term investor concern, contributing to a large negative move earlier in the week. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Coverage pieces framed the results as “in line” but stressed the deteriorating outlook and ongoing industry headwinds, which has kept selling pressure on the shares after the initial post-earnings bounce. Elevance reports Q4 in line with expectations but stock drops

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.